Abstract Percutaneous mitral balloon valvotomy (MBV) was introduced in 1984 by Inoue who developed the procedure as a logical extension of surgical closed commissurotomy. Since then, MBV has emerged as the treatment of choice for severe pliable rheumatic mitral stenosis (MS). With increasing experience and better selection of patient, the immediate results of the procedure have improved and the rate of complications declined. When the reported complications of MBV are viewed in aggregate, complications occur at approximately the following rates: mortality (0-0.5%), cerebral accident (1-2%), mitral regurgitation (MR) requiring surgery (0.9-2%). These complication rates compare favorably to those reported after surgical commissurotomy. Several randomized trials reported similar hemodynamic results with MBV and surgical commissurotomy. Restenosis after MBV ranges from 4% to 70% depending on the patient selection, valve morphology, and duration of follow-up. Restenosis was encountered in 31% of the author's series at mean follow-up of 9 ± 5.2 years (range 1.5-19 years) and the 10, 15, and 19 years restenosis-free survival rates were (78 ± 2%) (52 ± 3%) and (26 ± 4%), respectively, and were significantly higher for patients with favorable mitral morphology (MES 6 8) at 88 ± 2%, 67 ± 4% and 40 ± 6%, respectively (P < 0.0001). The 10, 15, and 19 years event-free survival rates were 88 ± 2%, 60 ± 4% and 28 ± 7%, respectively, and were significantly higher for patients with favorable mitral morphology 92 ± 2%, 70 ± 4% and 42 ± 7%, respectively (P < 0.0001). The effect of MBV on severe pulmonary hypertension, concomitant severe tricuspid regurgitation, left ventricular function, left atrial size, and atrial fibrillation is addressed in this review.
mitral valve orifice to permit adequate cardiac output at a tolerable left atrial pressure. Starting over 50 years ago a variety of surgical techniques were developed; first closed commissurotomy followed by open commissurotomy after the introduction of the cardiopulmonary bypass. 1, 2 Mitral balloon valvotomy was introduced in 1984 by the Japanese surgeon Inoue, who developed the procedure as a logical extension of surgical closed commissurotomy. 3 Since then, MBV has emerged as the treatment of choice for severe pliable rheumatic mitral stenosis. The mechanism by which both procedures reduce stenosis is the same and involves mechanical dilatation of fused commissures. 4 Several randomized trials reported similar hemodynamic results with balloon valvotomy and surgical commissurotomy. However, periprocedural complications in surgical patients were somewhat higher. [5] [6] [7] [8] Both forms of commissurotomy eliminate the risks common to prosthetic valves, which include primary valve failure, thromboembolism, and endocarditis. The purpose of this review is to summarize the immediate and long-term results up to 19 years of MBV, its complications, and elucidate the effect of MBV on severe pulmonary hypertension, concomitant severe tricuspid regurgitation, left ventricular function, left atrial size, and atrial fibrillation.
Techniques
The transseptal technique is the most common technique used to perform MBV. The technique consists of advancing a catheter over the wire across the interatrial septum after transseptal puncture, enlarging the opening and advancing one large balloon (Inoue balloon) or two smaller balloons (double-balloon technique) across the mitral orifice and inflating them within the orifice. Although acute and short-term outcomes differ little between these two techniques, 9 ,10 complications such as death, left ventricular perforation, and stroke appear to be less common with the Inoue balloon. The multiple advantages of the Inoue balloon, include low profile of the device, the elimination of the stiff guide wire (minimizing the risk of LV perforation), easy maneuverability, and the stepwise dilation (gradual increase of balloon size on sequential inflations). 11 
Echocardiographic evaluation
Echocardiography is the mainstay of the noninvasive evaluation of mitral stenosis. The transthoracic echocardiography provides an evaluation of the valvular apparatus, mitral valve area (MVA), left atria dimension, and associated valve lesions. Doppler echo provides hemodynamic evaluation including mean mitral gradient, MVA, assessment of concomitant tricuspid regurgitation (TR) and estimation of pulmonary artery pressure. The morphologic evaluation of the mitral valve is semiquantilated using echocardiographic score (echo score). The scoring system evaluates leaflet thickening, mobility, calcification, and subvalvular involvement on a scale of 0-4, as described by Wilkins et al. 12 The mitral valve morphology is considered favorable if the mitral echocardiographic score (MES) is 68. Transesophageal (TEE) echo should be performed before MBV for patients with atrial fibrillation or prior history of systemic embolism or very obese patient where the left atrium was not properly visualized. We do not recommend TEE as a routine procedure before MBV. 13 
Results

Immediate hemodynamic results
The left atrial pressure, mean mitral gradient, and pulmonary artery systolic pressure decreased significantly after MBV with a corresponding increase in MVA. In the National Heart, Lung Blood Institute Balloon Valvotomy Registry of 736 patients, 14 the MVA by echocardiographic assessment was 1.09 ± 0.29 cm 2 before the procedure and increased to 1.8 ± 0.15 cm 2 after the procedure. In the author's series, 547 consecutive patients 13 the echocardiographic MVA was 0.92 ± 0.17 cm 2 before the procedure, and increased to 1.95 ± 0.29 cm 2 after the procedure. A significant inverse relationship was found between the echo score and post-procedure MVA where mitral valve morphology was found to be a strong predictor of post-procedure mitral opening. 12, 15 However, good results could also be obtained in cases with relatively high echo score.
Complications of balloon mitral valvotomy
In general, MBV is a safe procedure with high success rate, particularly if the patients chosen have optimal valve morphology as determined by echo score. When the reported rates of complications of MBV are viewed in aggregate, complications appear to occur at approximately the following rates: mortality (0-0.5%), cerebrovascular accident (CVA) (0.5-2%), cardiac tamponade (0.7-1%), mitral regurgitation requiring surgery (0.9-2%), mitral regurgitation of some degree (15%), and atrial septal defect detected by color Doppler (20-23%) which, however, closes or decreases in size in most patients. 11, 16, 17 4.3. Long-term follow-up and predictors of restenosis and eventfree survival
Mitral restenosis
The restenosis rate after MBV has been reported as 39% at 7 years 18 and was lower (31%) at 19 years in our younger population (mean age 31.5 ± 11 years) 19 and was 20% in subgroup of patients with MES 6 8. The actuarial freedom from restenosis rates for this population were 78 ± 2% at 10 years, 52 ± 3% at 15 years, and 26 ± 5% at 19 years and were significantly higher for patients with optimal morphology echo score 6 8, namely 88 ± 2% at 10 years, 67 ± 4% at 15 years, 40 ± 6% at 19 years (Fig. 1) . The predictors of being free from restenosis were a low echo score (P < 0.0001) and post-procedure MVA P 2.0 cm 2 .
19-21
Event-free survival
Iung et al. reported an event-free survival (survival with freedom from redo MBV, MVR, cardiac death, NYHA functional class III or IV) rate of 61% at 10 years in 528 patients with successful PMBV (mean age, 49 years). 21 Palacios et al. (879 patients with successful MBV mean age, 55 years) reported a rate of 38% at 12 years for patients with echo score 68 and 22% for patients with echo score >8. 22 Event-free survival rates at 10, 15, and 19 years were 88%, 60%, and 28%, respectively, in our relatively younger patients and were significantly higher for patients with MES 6 8 (92%, 70%, 42%, respectively; P < 0.0001). The predictors of event-free survival were low echo score and baseline A.F (P < 0.0001 and P = 0.014, respectively) 19 (Fig. 2) .
Regression of severe pulmonary hypertension
Pulmonary hypertension frequently complicates mitral stenosis and may significantly influence the clinical findings and prognosis of this condition. The increase in pulmonary arterial pressure is often out of proportion to the degree of left atrial hypertension, reflecting a major increase in pulmonary vascular resistance. 23, 24 To elucidate the effect of MBV on severe pulmonary hypertension, the author studied 559 consecutive patients with severe MS undergoing successful MBV. Patients were allocated to three groups on the basis of their pulmonary artery systolic pressure (PASP) at cardiac catheterization prior to MBV; group A (n = 345; 62%) had mild pulmonary hypertension (PASP < 50 mmHg); group B (n = 183; 33%) had moderate pulmonary hypertension (PASP 50-79 mmHg); and group C (n = 31; 5%) had severe pulmonary hypertension (PASP P 80 mmHg). Immediately following valvotomy, the PASP normalized in group A, in group B and C, pulmonary hypertension decreased slightly with further substantial regression occurring overtime (Fig. 3) and severe pulmonary hypertension normalized over 6-12 months in patients with successful PMBV and follow-up MVA P 2.0 cm 
Regression of significant tricuspid regurgitation
Significant tricuspid valve regurgitation (TR) is a common finding in patients with severe MS and in the majority of cases, it is functional, resulting from right ventricular and tricuspid annular dilation caused by long standing pulmonary hypertension. Although earlier reports suggested that TR can resolve once the diseased mitral valve is replaced, 27, 28 the results of later studies are contradictory. 29, 30 We and other investigators demonstrated regression of significant TR after successful MBV in relatively young patients (mean age 25 ± 10 years) with severe MS and concomitant significant pulmonary hypertension (70 ± 22 mmHg). 31, 32 On the other hand, Sagie et al. 33 reported no regression of TR in relatively older patients (mean age 57 ± 15 years) with severe MS and mild pulmonary hypertension (46 ± 15 mmHg). We demonstrated that severe pulmonary hypertension is a strong predictor of regression of severe TR after MBV. 31 
Effect of mitral valvotomy on left ventricular function
In most cases of mitral stenosis, the left ventricular contractility is normal. However, in about one third of patients with mitral stenosis left ventricular systolic function is reduced. Preload reduction -caused by limited mitral inflow -and increased afterload -precipitated by reflex vasoconstriction secondary to decreased cardiac output, act in concert to reduce ejection performance. 34 We have demonstrated normalization of impaired LV systolic function after successful MBV in patients with severe MS. 35 
Effect of MBV on left atrial size
Significant reduction of LA size following successful mitral Valvotomy was demonstrated by several investigators. [36] [37] [38] To demonstrate the effect of MBV on left atrial size, 205 consecutive patients (mean age 31 ± 11 years) were studied by the author. LA size at baseline and at mean follow-up of 31 ± 21 months after successful MBV (post-procedure MVA P 1.5 cm 2 , MR 6 214) was analyzed. LA anteroposterior dimension decreased in 87% of the patients (from 48.7 ± 7 to 42 ± 6.6 mm; P < 0.0001) whereas in 13%, it remained unchanged or even increased. Similarly, LA volume was decreased in 93.5% of patients (from 92 ± 29 to 61 ± 24 cm 3 ; P < 0.0001) whereas in the remaining 6.5% of patients it remained unchanged or even increased. LA antero- Figure 1 Freedom from restenosis by Kaplan-Meier estimates for all patients and for patients with MES 6 8. Numbers at the bottom represent patients alive and uncensored at each year of follow-up.
posterior dimension returned to normal in 29.2% of patients in sinus rhythm and in none of the patients with AF. Multiple linear stepwise regression analysis was used to identify predictors of regression of LA size after MBV. The variables included in the analysis were gender, age, baseline anteroposterior LA dimension, baseline and post-procedure echo MVA, echo score, and baseline AF. Only two of these variables (baseline anteroposterior LA dimension and baseline AF) were shown to be predictors of regression of LA dimension (P < 0.001). 37 
Effect of MBV on the incidence of atrial fibrillation
We demonstrated a favorable effect of MBV on the longterm incidence of chronic AF (8.9%) in patients with severe MS 39 in comparison with the historical controls (29%) of patients with severe MS and similar baseline characteristics who were not submitted to intervention. 40 The predictors of AF were age, large LA > 40 mm, small MVA (61.5 cm 2 ) at follow-up. 
Comparison of mitral balloon valvotomy with surgical commissurotomy
MBV is associated with less morbidity, shorter hospital stay, avoidance of the discomfort and other problems associated with thoracotomy, while the cost of surgery is at least twice that of balloon Valvotomy in the United States. 41 The immediate results appear to be very similar to closed and open surgical commissurotomy 6, 8 while operative mortality from closed commissurotomy was 2.97% 42 which was higher than that reported after MBV (0-0.5%).
14 The only long-term, though relatively small (30 ) and lower restenosis rate (6%, 6%, and 37%). 8 In long-term surgical series Hickey et al. reported on 103 patients with closed commissurotomy (mean age 38 years) event-free rate from mitral valve replacement of 78% at 10 years and 47% at 20 years. 43 Rihal et al. reported on 267 patients' (mean age 43 years) event-free rate from MVR 57% at 10 years and 24% at 20 years. 44 In our series, the combined event-free rates after MBV are 88% at 10 years, 60% at 15 years, and 28% at 19 years which were not worse than those of surgical series. 19 
Conclusions
Mitral balloon valvuloplasty, which is the procedure of choice in the treatment of rheumatic mitral stenosis, has excellent immediate and long-term results in patients with favorable mitral valve morphology but those with less favorable anatomy may still have reasonably good hemodynamic and symptomatic relief. This technique is associated with less morbidity and long-term results are better than the historical reported surgical results. The long-term outcome can be predicted from baseline clinical and valvular characteristics. MBV is safe and effective when treating patients with MS and severe pulmonary hypertension, the latter condition being normalized over 6-12 months after successful MBV. Severe TR regresses after successful MBV in the presence of severe pulmonary hypertension. Severely impaired LV systolic function normalized after successful MBV.
